stockTarget News & Analysis
3 articles
Market Mood
H.C. Wainwright Raises Palvella Therapeutics Price Target to $270
H.C. Wainwright has increased its price target for Palvella Therapeutics to $270 per share. This adjustment reflects a change in the expected value of the company, which could influence investor sentiment and trading behavior. The updated target suggests a new valuation based on current market conditions, which may impact the stock's performance. The previous target was not specified.
Read More
Crown Castle (CCI) Receives $102 Price Target Amid Dish Cancellation Impact
Crown Castle Inc. (NYSE: CCI) received an 'Outperform' rating and a price target of $102 from Bernstein SocGen Group. The firm forecasts low single-digit revenue growth following a slump in 2026 due to $3.5 billion in contract cancellations by Dish Network, which accounted for about 5% of Crown Castle’s total annual site rental revenue by the end of 2025. Crown Castle's earnings per site stand at $102, compared to competitors American Tower and SBA Communications at $125,000 and $107,000 respectively. The company's portfolio includes over 40,000 cell towers, and Bernstein anticipates carrier renewals will yield approximately a 3% year-over-year increase, excluding losses from Sprint and Dish.
Read More
Stifel Increases Ciena Price Target to $430 Driven by AI Networking Growth
Stifel has raised its price target for Ciena to $430, aligning with growth trends in AI networking. This adjustment reflects the anticipated market potential as AI technologies are increasingly adopted in networking solutions. The new price target indicates a significant upside potential from Ciena's current trading levels. This move could positively influence investor sentiment towards Ciena and the AI networking sector as a whole.
Read More